These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 28974368)

  • 1. Correlation of pharmacokinetics and brain penetration data of adult zebrafish with higher mammals including humans.
    Kulkarni P; Medishetti R; Nune N; Yellanki S; Sripuram V; Rao P; Sriram D; Saxena U; Oruganti S; Yogeeswari P
    J Pharmacol Toxicol Methods; 2017; 88(Pt 2):147-152. PubMed ID: 28974368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Bioavailability and Disposition protocol: A novel higher throughput approach to assess pharmacokinetics and steady-state brain distribution with reduced animal usage.
    Fu T; Gao R; Scott-Stevens P; Chen Y; Zhang C; Wang J; Summerfield S; Liu H; Sahi J
    Eur J Pharm Sci; 2018 Sep; 122():13-21. PubMed ID: 29857045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics.
    Fan J; de Lannoy IA
    Biochem Pharmacol; 2014 Jan; 87(1):93-120. PubMed ID: 24055064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan and temozolomide brain distribution: a focus on ABCB1.
    Goldwirt L; Beccaria K; Carpentier A; Farinotti R; Fernandez C
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):185-93. PubMed ID: 24867782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
    de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
    J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
    Poujol S; Bressolle F; Duffour J; Abderrahim AG; Astre C; Ychou M; Pinguet F
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):292-305. PubMed ID: 16369821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
    Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
    Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.
    Goldwirt L; Lemaitre F; Zahr N; Farinotti R; Fernandez C
    J Pharm Biomed Anal; 2012 Jul; 66():325-33. PubMed ID: 22551773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
    Poujol S; Pinguet F; Ychou M; Abderrahim AG; Duffour J; Bressolle FM
    Oncol Rep; 2007 Dec; 18(6):1613-321. PubMed ID: 17982652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.
    Khatri A; Gaber MW; Brundage RC; Naimark MD; Hanna SK; Stewart CF; Kirstein MN
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):721-31. PubMed ID: 21161529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
    Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.
    Adiwijaya BS; Kim J; Lang I; Csõszi T; Cubillo A; Chen JS; Wong M; Park JO; Kim JS; Rau KM; Melichar B; Gallego JB; Fitzgerald J; Belanger B; Molnar I; Ma WW
    Clin Pharmacol Ther; 2017 Dec; 102(6):997-1005. PubMed ID: 28445610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Irinotecan pharmacokinetics].
    Chabot GG; Robert J; Lokiec F; Canal P
    Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
    Chang TC; Shiah HS; Yang CH; Yeh KH; Cheng AL; Shen BN; Wang YW; Yeh CG; Chiang NJ; Chang JY; Chen LT
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):579-86. PubMed ID: 25577133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.
    Peigné S; Fouliard S; Decourcelle S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):29-43. PubMed ID: 26578442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
    Mallick P; Shah P; Gandhi A; Ghose R
    Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.